All News

What drives fate of synovial fibroblast into being a lining fibroblast? Presti et al., organoid culture approach: -Beta catenin seems instrumental -Cadherin 23 is specific & drives compaction Big implications for elective FLS targeted ttmt! @RheumNow #ACR23 ABST2426 https://t.co/9R5AhwE9rQ
Aurelie Najm  ( View Tweet)
Lung cancer in RA. @NamrataRheum et al. 26,625 RA HR for lung cancer for b/tsDMARDs vs csDMARDS 1.07 (0.91-1.26) Abstr#0453 #ACR23 @RheumNow https://t.co/NLNtyYoaoH https://t.co/tRpt62n62X
Richard Conway  ( View Tweet)
Comorbidities, including heightened CV risk, are linked to severe psoriasis. However, understanding subclinical CV disease timing in psoriasis patients remains limited. Dr. Jack Cush at .@RheumNow explains why more research is needed in this area: https://t.co/3KqQavVEbP https://t.co/Xo8SH0RTh9
RWCS RWCSmtg ( View Tweet)
@rheumnow and Dr Kevin Winthrop #ACR23 - watch what they to say about #COVID #vaccines on https://t.co/2zKD625Yn9 https://t.co/9tCOgNLyO7

Links:

TheDaoIndex KDAO2011 ( View Tweet)
MANDARA -52wk,ph3 non-inferiority study comparing efficacy & safety of benralizumab & mepolizumab in EGPA receiving SOC 👉Benralizumab was non-inferior to mepolizumab in achieving remission at wks 36 & 48 (2.71%; 95% CI –12.54, 17.96; p=0.7278) #ACR ABSTL14 @RheumNow #ACRbest https://t.co/S3aa3g5mnN
sheila  ( View Tweet)
K-drama! Korean database noted smokers and ex-smokers had less OA fewer TKR! These were age, comorbidities matched. Unclear what the data is for sex difference or occupation. Other pubs in the past noted similar observations. Abst#1808 @rheumnow #ACR23 @UnaMakris https://t.co/ZkjWoxD8wD
TheDaoIndex KDAO2011 ( View Tweet)
#ACR23 Abstr#2270 What are the causes of discordance btw #SLE patients and physicians pertaining to disease activity? Survey data from Global COVAD: 45% rate of discordance! Could be related to fatigue levels, pain, poor mental being & impaired physical function @RheumNow https://t.co/kVzGRJm2R8
Md Yuzaiful Md Yusof  ( View Tweet)
Great research by @andreafava on urinary biomarkers for lupus nephritis A#0850 #ACR23 IL-17 and other biomarkers can predict renal fxn loss - better than proteinuria! Article on @RheumNow https://t.co/DeiWFKzNxC

Eric Dein  ( View Tweet)

Vasculitis patients associated with increased pregnancy risks Large study of >600 pregnancies in >500 pts Vasculitis pts higher frequency of spontaneous abortion, elective termination, ectopic and molar pregnancy, preterm delivery 12% pre-eclampsia @RheumNow #ACR23 Abs#2425 https://t.co/Nqa77nxSFu
Robert B Chao, MD  ( View Tweet)
Pregnancy outcome in Vasculitis - Claim database study A#2425 #ACR23 @RheumNow 665 vasculitis pts, LVV 60, MV 160, SVV 217, variable 250 Incr risk of preterm delivery, particularly medically-ind deliv, esp Small vessel vasc (5x risk med-induced) Higer risk pre-eclampsia/eclampsia https://t.co/bWMyY5oqNK
Eric Dein  ( View Tweet)
Who knew @FDA_Drug_Info presented #ACR23 posters?! I thought they just issue statements if there was information to be shared! Abst#1822 Bari and Toci use during the pandemic for #COVID19 did not show new safety signals. 1 case HBV reactivation with bari @RheumNow https://t.co/zd7TELsV2j
TheDaoIndex KDAO2011 ( View Tweet)
International collaborative has discussed early referrals for PMR - this is what they’re recommending Better plans to get the right patients into rheumatologists is a big part of helping #MakeRheumForPMR ABST2395 #ACR23 @RheumNow https://t.co/Kea07IGxhG
David Liew drdavidliew ( View Tweet)
Antifibrotics in RA-ILD @Juge_P_A Discontinuation in 46% (Mainly GI). Improved FVC trajectory - almost stops decline. Abstr#2479 #ACR23 #ACRbest @RheumNow https://t.co/nZW6TVKefL https://t.co/5BX3PhFhOK
Richard Conway  ( View Tweet)
Rashes in Rheumatology at #ACR23 Name the rash? @Rheumnow https://t.co/7CNqOESctW

Links:

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#ACR23 Abstr#2334 Can we achieve #SLE DORIS remission with current therapy? Post-hoc analyses of 3 x RCTs + LTE over 4 years showed anifrolumab therapy was associated with more frequent and sustained remission vs PBO during the 4-year period. Good for long-term outcomes @RheumNow https://t.co/eq02yChTZr
Md Yuzaiful Md Yusof  ( View Tweet)
Rashes in Rheumatology at #ACR23 Name the rash? @Rheumnow https://t.co/uFjXEOHczZ

Links:

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Dysautonomia & joint hypermobility/hEDS - we all know that patients often have both, but what groups of symptoms cluster for patients? This French study showed three main groups - need to look at treatment strategies for each group individually #ACR23 ABST1838 @RheumNow https://t.co/UDepsudpXx
David Liew drdavidliew ( View Tweet)
TM83 #ACR23 @RheumNow 45yo M b/l sacroiliitis, Rx MTX -> ADA -> MTX + Tofa. No improv Low Ca, & Phos, ALP 239. Nml Vit D, High PTH. DEXA: Osteoporosis FGF23 high PET/CT showed soft tissue density in nasal septum, few cortical breaks Dx: oncogenic osteomalacia 2/2 malignancy https://t.co/EOcYNtovBy
Eric Dein  ( View Tweet)
Review of rashes in SLE at #ACR23 by Dr. Katherine Shaw, MD ⭐️Important to recognize rashes of lupus b/c heterogeneity of cutaneous lupus erythematosus subtypes influences response to treatment. @RheumNow https://t.co/u7dwDe9kbt
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Real-world tolerability of anti-fibrotics (nintedanib, pirfenidone) in RA-ILD @BrighamWomens: patients do drop out because of AEs, but a decent chunk are okay and do get modest benefit @Juge_P_A @jeffsparks #ACR23 ABST2479 @RheumNow https://t.co/BpM14eizmF
David Liew drdavidliew ( View Tweet)
×